Citigroup
ARGS

Citigroup’s Argos Therapeutics, Inc. ARGS Stock Holding History

Citigroup’s Portfolio ARGS Stock Details ARGS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Hold
0
– – – 7717
2017
Q2 		– Sell
-2
Closed -$17 – 7726
2017
Q1 		$0 Sell
2
-724
-100% -$45.8K ﹤0.01% 7563
2016
Q4 		$71K Buy
726
+667
+1,131% +$62.4K ﹤0.01% 5980
2016
Q3 		$6K Buy
59
+5
+9% +$522 ﹤0.01% 6748
2016
Q2 		$7K Buy
+54
New +$7.21K ﹤0.01% 6707
2016
Q1 		– Hold
0
– – – 8254
2015
Q4 		– Sell
-8
Closed -$1K – 8327
2015
Q3 		$1K Buy
8
+7
+700% +$829 ﹤0.01% 7324
2015
Q2 		$0 Hold
1
– – ﹤0.01% 8158
2015
Q1 		$0 Sell
1
-8
-89% -$1.39K ﹤0.01% 7846
2014
Q4 		$2K Buy
+9
New +$1.62K ﹤0.01% 6930
2014
Q3 		– Sell
-206
Closed -$33K – 7663
2014
Q2 		$33K Buy
+206
New +$34.1K ﹤0.01% 5473

Other funds holding ARGS

PI
Pharmstandard International Luxembourg $29M AUM 3.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SMH
Sanders Morris Harris Houston, Texas $172M AUM 22.54% 1-Year Est. Return
KeyBank National Association
KeyBank National Association Cleveland, Ohio $27.4B AUM 24.17% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

Citigroup's ARGS Position: Q3 2017 in Review

Citigroup held its Argos Therapeutics, Inc. (ARGS) position steady in Q3 2017 at 0 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #7717.

Citigroup first reported a position in ARGS in Q2 2014 and has held it in 9 quarters since. The position peaked at $71K in Q4 2016. 29 funds tracked by Wall St. Rank hold ARGS as of Q3 2017.

  • Citigroup held 0 shares of Argos Therapeutics, Inc. worth $0 as of Q3 2017.
  • Citigroup left its Argos Therapeutics, Inc. share count unchanged in Q3 2017.
  • Argos Therapeutics, Inc. made up ﹤0.01% of Citigroup's portfolio in Q3 2017, its #7717 holding.
  • Citigroup first reported a position in Argos Therapeutics, Inc. in Q2 2014 and has held it in 9 quarters since.
  • Citigroup's Argos Therapeutics, Inc. position peaked at $71K in Q4 2016.
  • 29 funds tracked by Wall St. Rank held Argos Therapeutics, Inc. as of Q3 2017.

Based on Citigroup's 13F filing for Q3 2017, filed 13 Nov 2017.